Aim to become one of the largest health science companies in Asia-Pacific
Japan-based Kirin Holdings Company Limited (Kirin Holdings) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) through a tender offer and share warrants under the Financial Instruments and Exchange Act to make FANCL a wholly-owned subsidiary.
Under the long-term management vision of Kirin Group Vision 2027, Kirin Holdings aims to “become a global leader in CSV by creating value in domains ranging from food & beverages to pharmaceuticals” by launching businesses in the health science field in addition to the food and pharmaceuticals fields, and by turning consumer health issues into growth opportunities. Through its research and development capabilities in fermentation and biotechnology as well as immunology, Kirin Holdings has strengthened its health science business to develop it into a business unit that will be responsible for the long-term growth of the Kirin Group. In 2019, Kirin Holdings acquired approximately 33 per cent of FANCL’s shares (based on voting rights) and entered into a capital and business alliance agreement. In 2023, Kirin Holdings acquired Blackmores Limited (Blackmores), an Australian company that operates a health food (natural health) business in the Asia-Pacific region, thereby gaining a solid business foundation in overseas markets.
